stockrowRani Therapeutics Holdings, Inc.
RANI Healthcare Biotechnology
Rani Therapeutics Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.6 million, up 58.9% from fiscal 2024.
- Revenue
- 0.00%
- EPS
- +77.8%
- Free cash flow
- −55.3%
Quarter to June 2026, against a year earlier
Follow RANI
Alert me
Rani Therapeutics Holdings, Inc. (RANI) EV/Sales
As of 6 November 2026, Rani Therapeutics Holdings, Inc. (RANI) trades at a EV/Sales of 12.6×. Over the past ten years it has ranged from 3.8× (September 2023) to 258× (November 2021); the current reading is higher than 15% of that period. That is above the Biotechnology industry median of 9.0× and above the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 15.4× | 20.88% |
| FY2024 | 12.7× | (90.93%) |
| FY2021 | 140× | 18.34% |
| FY2020 | 119× | 0.00% |
| FY2019 | 119× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 20.7× | (33.28%) |
| Mar 2026 | 31.1× | 101.68% |
| Dec 2025 | 15.4× | (5.75%) |
| Mar 2025 | 16.3× | (88.37%) |
| 6 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| OKYO OKYO Pharma Limited Sponsored ADR compare | n/m |
| TNYA Tenaya Therapeutics, Inc. compare | n/m |
| ACRV Acrivon Therapeutics, Inc. compare | n/m |
| CLLS Cellectis S.A. compare | 0.2× |
| CSBR Champions Oncology, Inc. compare | 1.0× |
| RANI Rani Therapeutics Holdings, Inc. | 12.6× |
| NRXS Neuraxis, Inc. compare | 12.8× |
| NTRB Nutriband Inc. compare | 39.8× |
| MNOV MediciNova, Inc. compare | 50.5× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)